Archive · 22 Nov 2025
Eli Lilly's Alzheimer's Drug Approved in India
Eli Lilly's new medicine, donanemab, has been allowed to be sold in India to help people with Alzheimer's disease in its early stages.
This disease is the most common cause of memory problems, and many more people in India are expected to have it in the future.
Eli Lilly gets CDSCO approval for donanemab in India
Drug treats Alzheimer's in early stages, including mild cognitive impairment and mild dementia
Donanemab is an IV infusion administered every four weeks
Alzheimer's is the most common cause of dementia, with 60-70% of cases
India's dementia cases estimated to reach over 8 million by 2030
- Who
- Eli Lilly and Company (India)
- What
- Received approval for donanemab, an Alzheimer's disease treatment
- When
- On Tuesday
- Where
- In India
- Why
- To treat Alzheimer's disease in its early stages
- Drug Name
- Donanemab
- Dosage
- 350 mg/20 mL IV infusion every four weeks
- Target Patients
- Adults with early symptomatic Alzheimer's, including mild cognitive impairment and mild dementia
- Regulatory Body
- Central Drugs Standard Control Organization (CDSCO)
- Estimated Dementia Cases in India by 2030
- Over 8 million